Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
Mohamad-Ali Salloum, PharmD • March 7, 2026
Share
Pharmacology
PK/PD
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
A clear guide for pharmacy students learning PK/PD the smart way. Short chunks. Visual cues. A quick quiz at the end.
Strong grip
= high MOR affinity
Weak push
= partial agonism
1) Quick History
Where Buprenorphine Came From
Developed in the late 1960s from thebaine(a poppy plant derivative), buprenorphine was designed to give useful opioid effects with a safer profile. It binds very strongly to μ‑opioid receptors (MORs) but only partially activates them.
Opioid Use Disorder (OUD)
Chronic Pain (select cases)
2) The Patient
Why Buprenorphine Is Needed
Classic opioid withdrawal may include: runny nose, yawning, dilated pupils, goosebumps, stomach cramps, anxiety, and fast heartbeat — all due to under‑stimulation of MORs.
⚠️
Critical rule:
Start buprenorphine only when moderate withdrawal
is present. If given too early, it can displace a full agonist and cause precipitated withdrawal.
3) Absorption
How Buprenorphine Enters the Body
Sublingual is the most common route because swallowing leads to extensive first‑pass metabolism. Under the tongue, it reaches systemic circulation directly.
Bioavailability
~30–50% (sublingual)
T max
1–4 hours
Protein binding
~96%
Half‑life
~24–37 hours
Naloxone in combo products has minimal sublingual absorption; it mainly matters if injected.
Hover the button to simulate absorption
4) Distribution
Where the Drug Travels
- Crosses the blood–brain barrier(high lipophilicity)
- Accumulates in fat — slow release over time
- Highly protein‑bound(~96%)
- Crosses the placenta and appears in breast milk
Memory hook: “Couch‑potato molecule”
— likes fat, stays longer.
5) Pharmacodynamics
What the Drug Does
MOR: Partial agonist
KOR: Antagonist
DOR: Antagonist/weak partial agonist
ORL‑1: Partial agonist
Show intracellular actions
- ↓ cAMP
- ↓ presynaptic Ca²⁺ → ↓ pain neurotransmitter release
- ↑ K⁺ efflux → hyperpolarization
✅
Clinical effects:
reduces withdrawal and cravings, provides analgesia, ceiling effect on respiratory depression
, and functionally blocks other opioids (very high MOR affinity). PET studies suggest ~ 70% MOR occupancy
helps suppress withdrawal and block opioid effects.
6) Metabolism
How the Body Breaks It Down
- Phase I – CYP3A4: buprenorphine → norbuprenorphine (active, poor CNS entry)
- Phase II – UGT1A1 & UGT2B7: glucuronidation → water‑soluble metabolites
Memory line:
“3A4 cuts, UGTs clean.”
CYP3A4 inhibitors ↑ levels
CYP3A4 inducers ↓ levels
Liver disease: adjust
Kidney disease: modest effect
7) Elimination
How It Leaves the Body
- ~70% via feces (major)
- ~30% via urine (mostly metabolites)
- Some enterohepatic recirculation
8) A → Z Story
One‑Glance Journey (Sublingual Dose)
A.
Patient arrives in moderate withdrawal.
B.
Sublingual film dissolves → absorbed through oral mucosa.
C.
Avoids first‑pass metabolism → enters systemic circulation.
D.
Travels in blood (mostly protein‑bound).
E.
Free drug crosses into the brain.
F.
Strong MOR binding → partial
activation.
G.
Withdrawal/cravings decrease; ceiling effect improves safety.
H.
Liver enzymes break it down (CYP3A4 + UGTs).
I.
Metabolites go to bile and kidneys.
Z.
Excreted in feces (major) and urine (minor).
9) Key Clinical Tips
High‑Yield for Students
- Start only in moderate withdrawal to avoid precipitated withdrawal.
- Typical OUD maintenance: 12–16 mg/day (individualize per labeling/clinical response).
- Watch CYP3A4 interactions(inhibitors ↑ levels; inducers ↓ levels).
- CNS depressants increase respiratory risk despite the ceiling.
- Acute pain is trickier due to receptor blockade — use multimodal strategies.
Check Yourself
Quick Quiz: Can You Recall the Essentials?
1) Why is sublingual buprenorphine preferred over oral swallowing?
2) The best time to start buprenorphine is:
3) Which statement is correct?
4) Main elimination route?
5) Quick metabolism memory aid:
References :
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw‑Hill; 2018.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology. 9th ed. Elsevier; 2020.
- Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59‑S77.
- SAMHSA. TIP 63: Medications for Opioid Use Disorder. Rockville, MD; 2018.
- Suboxone® (buprenorphine/naloxone) sublingual film. U.S. Prescribing Information. Indivior.
- Kuhlman JJ Jr, et al. Human pharmacokinetics of sublingual buprenorphine. J Anal Toxicol. 1996;20(6):369‑378.
- Rouguieg‑Malki K, et al. Contribution of UGTs and CYP3A4 to buprenorphine metabolism. Drug Metab Dispos. 2011;39(12):2059‑2066.
- Dahan A, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627‑632.
- Greenwald MK, et al. Buprenorphine dose, MOR occupancy, and blockade of opioid effects. Neuropsychopharmacology. 2003;28(11):2000‑2009.
- Lund IO, et al. Pregnancy outcomes on buprenorphine vs methadone. Addiction. 2013;108(2):255‑262.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References : American Chemical Society. Tramadol – Molecule of the Week Archive. December 16, 2014. [acs.org] DEA Diversion Control Division. Tramadol Drug & Chemical Evaluation Section Report. April 2025. [deadiversi....usdoj.gov] Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879‑923. [go.drugbank.com] Food and Drug Administration (FDA). ULTRAM® (tramadol hydrochloride) tablets label. 2004. [accessdata.fda.gov] Nickson C. Tramadol – CCC Pharmacology. Life in the Fast Lane ; 2024. [litfl.com] DrugBank Online. Tramadol: Uses, Interactions, Mechanism of Action. DB00193. [go.drugbank.com] Food and Drug Administration (FDA). Tramadol Hydrochloride Tablets (DailyMed). 2023. [dailymed.nlm.nih.gov] Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries . 2015. [ncbi.nlm.nih.gov] Food and Drug Administration (FDA). Tramadol ER Capsules Label Information. 2010. [accessdata.fda.gov] EBM Consult. Mechanism for Tramadol‑Induced Serotonin Syndrome in Patients Taking SSRIs. 2017. Medsafe Pharmacovigilance. Serious Reactions with Tramadol: Seizures and Serotonin Syndrome. 2007. Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1–6. Medscape Reference. Ultram, ConZip (tramadol) dosing, indications, interactions. 2026.
A thoughtful reflection on Declutter Your Mind, exploring mental clutter, awareness, negative thinking patterns, mindfulness, and practical habits for mental clarity.
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
A clear, evidence‑based guide to Ramadan fasting, explaining its metabolic, mental, and cardiometabolic benefits, plus practical nutrition, hydration, sleep, and medication strategies for healthy adults and high‑risk patients.
A practical guide to shifting from blaming “human error” to applying ICH GCP E6(R3) system‑level quality, Quality by Design, and risk‑based oversight to prevent repeat deviations in clinical trials.
Learn 5 Whys and Fishbone (Ishikawa) for Root Cause Analysis in clinical research, with practical examples and an interactive quiz—no fluff, just clarity.
A clear, practical guide to CAPA for Clinical Research Associates—covering corrective and preventive actions, real‑world scenarios, and an interactive quiz to reinforce learning.
Boost your health with a simple 30‑minute morning walk backed by science—better heart health, mood, sleep, and energy.
